Lantern Pharma Adds VP of Clinical Development, Additional Team Members

Lantern Pharma is a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development.

Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members.

Lantern Pharma is a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development.

The startup said the expansion of the clinical development team will continue to advance the Harmonic trial, a Phase 2 trial for never smokers with NSCLC, as well as the upcoming first-in-human Phase 1 clinical trials for Lantern’s drug candidates LP-184 and LP-284, which are both anticipated to launch in mid-2023.

NSCLC is any type of epithelial lung cancer other than small cell lung cancer.

“We are looking forward to the many contributions that Dr. Ewesuedo and our expanded clinical development team will bring to Lantern and our clinical programs,” Panna Sharma, Lantern’s president and CEO, said in a statement. “They are joining Lantern at a pivotal period in our company’s growth as we advance our drug candidates into and through clinical trials. I am confident in the decades of proven experience of our new team members and their ability to progress Lantern’s drug candidates to improve the lives of cancer patients,” continued Sharma.

Experience in clinical development

Ewesuedo has more than 20 years of experience in preclinical, early, and late phase drug development including roles in clinical development leadership at AstraZeneca, Genzyme/Sanofi, Pfizer, Tesaro/GlaxoSmithKline, and Kymera.

He has helped lead the development of several drugs including the successful filings for Trazimera (trastuzumab), Nyvepria (pegfilgrastim), and Zirabev (bevacizumab), while he was at Pfizer.

He also served as a clinical research faculty member at The Ohio State University from 2000-2005. 

Lantern also recently appointed Ernest Kitt as head of clinical operations. Kitt has more than 20 years of experience in oncology drug development and clinical operations with proven success in bringing drugs to market. He has held clinical oncology leadership positions at companies including Amgen/Onyx, Aptose, and Biosplice.

The startup said that other additions to the clinical development team include Annum Zhara as a senior clinical trial project manager and Brianna MacCrory as a clinical trial navigator.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.  

R E A D   N E X T

  • Reveles' new DCT management platform broadens access to clinical trials by enabling patients to participate—without leaving their homes. The technology includes enabling eConsent from existing and potential patients; online video and audio between patients and healthcare providers; direct data collection including real-time data, compliance, and status view featuring eSource, eDiaries, devices, wearables, questionnaires, and surveys; and telemedicine tools.

  • Anything Liquid to relocate to Fort Worth suburb from Southern California

    The online pharma company specializes in liquid dietary supplement manufacturing, sales, and distribution.

  • The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform. Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.

  • The Cancer Prevention & Research Institute of Texas has provided more than $3.1 billion in funding toward the development of cancer-fighting therapeutics, devices, diagnostics, and tools since 2010. It's now issued a call for startups and early-stage companies to apply for product development research grants for the 2023 fiscal year. “CPRIT’s mission is to invest in the research prowess of Texas institutions while expediting breakthroughs in cancer cures and prevention,” CEO Wayne Roberts said last May.

  • The Cancer Prevention and Research Institute of Texas approved over $90 million in new cancer research and prevention grants at its quarterly meeting near the Texas Capitol on Wednesday—and $20.6 million of that money is coming to North Texas to advance everything from breast cancer and lung cancer screening to "deep learning models" to facilitate T-cell receptor therapies.